Encapsulation of Cinnamaldehyde using Chitosan: Stability, Mucoadhesive and Cinnamaldehyde Release

Purbowatinipriddyum Ria Sarjono a,*, Ngadiwiyana a, Enny Fachriyah a, Ismiyarto, Nor Basid Adiwibawa Prasetya a, Khikmah a

a Chemistry Department, Faculty of Sciences and Mathematics, Diponegoro University, Jalan Prof. Soedarto, Tembalang, Semarang

* Corresponding author: purbowatinipriddyum@gmail.com

https://doi.org/10.14710/jksa.21.4.175-181

Abstract

Cinnamaldehyde contained in cinnamon oil is useful as an antidiabetic; however, it has very low oral bioavailability. One effort to increase oral bioavailability of cinnamaldehyde is by encapsulation using chitosan. Encapsulation of cinnamaldehyde in chitosan has been successfully made in the form of powder. The aim of this study was to obtain data of stability, mucoadhesive and cinnamaldehyde release from cinnamaldehyde encapsulated chitosan. Stability tests were performed physically and chemically. Mucoadhesive tests were carried out in vitro and in vivo, which were granule fabrication and then mucoadhesive test. The results showed that the levels of cinnamaldehyde decreased within 4 weeks, from the first to the fourth week 100%; 99.87%; 98.85%; 97.33%, respectively. Cinnamaldehyde powder did not change significantly in specific gravity, pH, centrifugation and organoleptic after a month. The release percentage of cinnamaldehyde in acidic media pH 2.0 for 180 minutes was 83.4%, whereas in alkaline media pH 7.4 for 360 minutes was 61%. The cinnamaldehyde encapsulated chitosan nanoparticle powder performed mucoadhesive capacity in the gastric mucosa and in the intestinal mucosa of 91.5% and 84.61%, respectively.

1. Introduction

Diabetes mellitus (DM) is a chronic disease characterized by a deficiency of insulin production and causes prolonged hyperglycemia with disruption in most metabolic processes in the human body [1]. In 2013, Basic Health Research (Riset Kesehatan Dasar, Riskesdas) reported that the number of people at the age over 15 years suffering DM in Indonesia was 6.9%. This result has nearly doubled compared to diabetes mellitus patients in 2007. The World Health Organization (WHO) also reported that in 2014, 8.5% of adults aged 18 years and over had diabetes and in 2015, diabetes was the direct cause of 1.6 million deaths [2].

Ngadiwiyana et al. [3] reported that cinnamaldehyde contained in cinnamon oil is useful as an inhibitor α-glucosidase; however, it has very low oral bioavailability. Yuan et al. [4] reported that the oral bioavailability of cinnamaldehyde was less than 20% at doses of 250 and 500 mg/kg. Formulation development in an effort to increase oral bioavailability of cinnamaldehyde were reported by encapsulation using chitosan.

Research conducted by Fernandes et al. [5] and Chuah et al. [6] showed that chitosan has mucoadhesive properties. The properties can extend the residence time and contact time of the drug at the site of the application or its absorption so as to enhance the bioavailability of the drug. It may increase the therapeutic effect of drugs that are sometimes limited by shorter residence times in the gastrointestinal tract [2]. In addition to having mucoadhesive properties, chitosan can be formulated as a matrix that releases bioactive compounds in a controlled manner so that the release of bioactive compound can be controlled on the diseased organ [8].
The encapsulation of cinnamaldehyde using chitosan was successfully made by Ariestiani et al. [9] in powder form with an encapsulation efficiency value of 74.39% and IC50 value in inhibiting α-glucosidase enzyme of 134.13 ppm. The result of this encapsulation can be used as pharmaceutical preparations that can improve bioavailability and control the release of cinnamaldehyde in the digestive system so that it can be utilized more effectively as anti-diabetic. Stability testing of drugs is necessary so that the benefits of the drug are not lost. Moreover, the testing of drug stability is essential for product quality. Pharmaceutical stability tests will show changes in the quality of drug products related to time under the influence of environmental factors, such as temperature, humidity and light. Stability testing is generally recommended during the development of new drug products [10]. By far there have been no studies reporting the stability, mucoadhesive properties and controlled release of chitosan nanoparticles coating cinnamaldehyde. Therefore, stability, mucoadhesive and release of cinnamaldehyde in chitosan nanoparticles were carried out in this study.

2. Experimental

2.1. Materials and equipments

The materials used in this study were the cinnamaldehyde encapsulated chitosan powder obtained as reported by Ariestiani et al. [11]; empty capsules; ethanol (pa, Merck); aquades; NaCl (Merck); 37% HCl (Lab Guard); Phosphate Buffered Saline (Biogear) as alkaline medium of pH=7.4; lactose monohydrate (Merck); stomach and intestine isolated from 3 month old wistar mice (Test Animal Laboratory of Medical Faculty of Diponegoro University).

The equipments used in this research were Climatic Chamber (ICO 50 Memmert), Incubator Memmert IN-30, UV–Vis Spectrophotometer (PG Instruments Limited Model T60U), Analytical (Ohaus), Centrifuge: PLC Series, Orbital Shaker (Tungtec Instruments CO., LTD), pH meters (LaMotte), standard glassware, mortar and pestle.

2.2. Stability Test of Cinnamaldehyde encapsulated Nanoparticle Chitosan Powder

Each 5 mg of encapsulated powder was packed into an empty capsule. Packaged encapsulated powder were put into a 100 mL brown bottle. Stability test of encapsulated powder were carried out chemically and physically. Chemical stability tests included measuring cinnamaldehyde content in encapsulated, specific gravity and pH. Physical stability test included centrifugation test and physical test (color, shape and smell). All encapsulated powder preparations were stored in the climatic chamber for 4 weeks with a temperature of 30°C and humidity of 75%, except for color, shape and odor which were stored at 4°C and 60°C. The temperature of sample at 4°C was carried out in freezer while the temperature of 60°C was in an incubator [12].

2.3. Chemical stability tests

2.3.1. Standard curve of cinnamaldehyde

The standard curve was made by measuring the absorbance of cinnamaldehyde solution in distilled water with a concentration of 4, 5, 6, 7, 8 ppm at a wavelength of 292 nm.

2.3.2. Percentage(%) of cinnamaldehyde contained in encapsulation (Load)

Encapsulated powder (1 mg) was dissolved in 10 mL of distilled water. The absorbance was measured using UV–Vis spectrophotometer at a wavelength of 292 nm. The absorbance was plotted into the standard curve equation, then the percentage of cinnamaldehyde contained in encapsulation was calculated using the formula (1)[13].

\[ \% Er = \frac{M_i}{M_t} \times 100\% \] (1)

Where: Er is the total cinnamaldehyde contained in encapsulation (load); Mi is mass of cinnamaldehyde in encapsulation obtained from absorbance measurements (mg/10 mL); and Mt is mass of encapsulation (mg/10 mL)

2.3.3. Measurement of cinnamaldehyde content

Encapsulated powder (1 mg) was dissolved in 10 mL of distilled water then the absorbance was measured using a UV–Vis spectrophotometer at a wavelength of 292 nm. The measurements were taken every week for 4 weeks. The absorbance obtained was plotted into the standard curve equation. The cinnamaldehyde content was calculated using the formula (2):

\[ \text{Cinnamaldehyde content} = \frac{M_i}{M_r} \] (2)

Where: Mi is mass of cinnamaldehyde in encapsulation obtained from absorbance measurements (mg/10 mL); and Mr is the total cinnamaldehyde contained in encapsulation.

2.3.4. Specific gravity

Specific gravity were measured using a picnometer. Picnometer was weighed (A1) then filled with encapsulated powder and weighed (A2). Afterwards, the pycnometer was cleaned, and then filled with distilled water and weighed (A3). Specific gravity measurement was carried out every week in 4 weeks. Specific gravity was calculated using the formula (3):

\[ \text{Specific gravity} = \frac{A_1-A}{A_1-A_3} \times 1 \] (3)

2.3.5. pH

A total of 5 mg of encapsulated powder was dissolved in 20 mL of distilled water then measured using a pH meter. pH measurements were carried out every week in 4 weeks.
2.4. Physical stability tests

2.4.1. Centrifugation test

A total of 5 mg of encapsulated powder was dissolved in 5 mL of distilled water then centrifuged at 3000 rpm for 10 minutes and observed. Centrifugation tests were carried out every week for 4 weeks.

2.4.2. Colour, shape and odor test

Every week for 4 weeks, the cinnamaldehyde encapsulated powder in chitosan nanoparticles was observed its color, shape and odor at 4°C, 37°C and 60°C.

2.4.3. In vitro test of cinnamaldehyde release in acidic medium at pH 1.2

The cinnamaldehyde release test from chitosan nanoparticles was carried out by inserting 1 mg of encapsulated powder into an erlenmeyer containing 10 mL of acidic media pH 1.2. The mixture was kept into the orbital shaker with a temperature of 37°C and a rotational speed of 100 rpm for 3 hours [14]. For every 20 minutes, absorbance was measured by taking 4 mL of the solution at a wavelength of 292 nm.

2.4.4. In alkaline medium at pH 7.4

The cinnamaldehyde release test from chitosan nanoparticles was carried out by inserting 5 mg of encapsulated powder into an erlenmeyer containing 50 mL of phosphate buffer pH 7.4. The mixture was kept into the orbital shaker with a temperature of 37°C and a rotational speed of 100 rpm for 6 hours [14]. For every 20 minutes, absorbance were measured by taking 4 mL of the solution at a wavelength of 292 nm.

The cinnamaldehyde release in both media were calculated using formula (4):

\[
\text{Percent release} = \frac{M_t}{M_i} \times 100\% \tag{4}
\]

Where: \(M_s\) is cinnamaldehyde mass released into the media; \(M_t\) is total mass of cinnamaldehyde in encapsulated powder.

2.5. In vitro mucoadhesive test

Mucoadhesive tests were carried out by in vitro in two stages, which were granule fabrication and then mucoadhesive test [15].

2.5.1. Granule fabrication

Granules fabrication was carried out by grinding the mucoadhesive granule formula until homogenous. Ethanol was then added until it formed a mass that can be clenched and then dried in an oven at 100°C for 10 minutes.

<table>
<thead>
<tr>
<th>Tabel 1. Granule formulation (F) for mucoadhesive test</th>
</tr>
</thead>
<tbody>
<tr>
<td>Materials</td>
</tr>
<tr>
<td>Encapsulated powder</td>
</tr>
<tr>
<td>Chitosan</td>
</tr>
<tr>
<td>Cinnamaldehyde</td>
</tr>
<tr>
<td>*PVP K30</td>
</tr>
<tr>
<td>Lactose</td>
</tr>
</tbody>
</table>

2.5.2. Mucoadhesive test

The mucoadhesive test were carried out in the gastric and intestinal mucosa isolated from male white rats aged 3 month old. The gastric was opened, washed with NaCl solution, then 10 granules were weighed and placed on the surface of the gastric and intestine for 5 minutes and tilted at an angle of 45°. The gastric was eluted with an acidic media solution of pH 1.2 while the intestine was eluted with a base media solution pH 7.4 for 10 minutes. Embedded granules were calculated using the formula (5):

\[
\text{Percent} = \frac{G_i}{G_t} \tag{5}
\]

Where: \(G\) is percentage of granules embedded into the gastric and intestine; \(G_i\) is mass of embedded granule after 10 minutes; and \(G_t\) is total mass of granules.

3. Results and discussion

3.1. Stability test

3.1.1. Chemical stability

Chemical stability was investigated through testing cinnamaldehyde content, specific gravity and pH changes.

3.1.2. Cinnamaldehyde content

Measurement of the cinnamaldehyde content in the encapsulated powder were carried out every week to determine its stability. The results are shown in Figure 1.

![Figure 1. Cinnamaldehyde content per week](image)

The cinnamaldehyde content in the first week was 100%. This shows that cinnamaldehyde in the encapsulation is stable in a week. Cinnamaldehyde levels
begin to reduce in the second to fourth week. After four weeks, the cinna
cmaldehyde content has decreased by 2.67%, which is probably influenced by temperature and
humidity causing the crosslinks between chitosan and tripolyphosphate begin to break and the chains between
polymer chitosan reattach each other (aggregation occurs) so that the encapsulated cinnamaldehyde starts
to release. Since the level of cinnamaldehyde after 4 weeks remains high at 97.33% with a half-life of 72
weeks, it can be concluded that the encapsulated powder is quite stable during storage under certain conditions.

3.1.3. Specific gravity
Specific gravity is the ratio of the weight of a substance to the weight of a standard substance at the
same volume and temperature. Specific gravity describes the relationship between the weight of a substance to the
weight of a standard substance [16]. Table 2 shows the specific gravity of encapsulated powder stored in the
climatic chamber for 4 weeks. It can be seen that encapsulated powders did not experience specific gravity
changes. In other words, the encapsulated powder remains stable even after 4 weeks of storage.

<table>
<thead>
<tr>
<th>Week</th>
<th>Specific gravity (g/mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>0.0059</td>
</tr>
<tr>
<td>2</td>
<td>0.0048</td>
</tr>
<tr>
<td>3</td>
<td>0.0045</td>
</tr>
<tr>
<td>4</td>
<td>0.0047</td>
</tr>
<tr>
<td>Mean</td>
<td>0.0050</td>
</tr>
</tbody>
</table>

3.1.4. pH
pH measurement aims to determine the pH value of the encapsulated powder preparation stored in the
climatic chamber for 4 weeks. pH is one of the parameters to test stability of the drug in a formulation. The pH value
of the encapsulated powder from the first week to the fourth week is shown in Table 3. Table 3 shows the pH value of encapsulated powder after 4 weeks remains stable at 6.7. This pH value of 6.7 shows that the encapsulated powder is acidic. The nature of this acid is influenced from hydrogen alpha position on carbonyl groups in cinnamaldehyde.

<table>
<thead>
<tr>
<th>Week</th>
<th>pH</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>6.71</td>
</tr>
<tr>
<td>2</td>
<td>6.67</td>
</tr>
<tr>
<td>3</td>
<td>6.65</td>
</tr>
<tr>
<td>4</td>
<td>6.72</td>
</tr>
<tr>
<td>Mean</td>
<td>6.7</td>
</tr>
</tbody>
</table>

3.2. Physical stability

3.2.1. Centrifugation
In this test, encapsulated powder formulation were centrifuged at 3000 rpm for 10 minutes. This
centrifugation test used to accelerate centrifugal force to separate two or more substances that have a different
density, such as between liquids or between liquids with a solid [17]. The results show no changes, in which two
phases still remains (liquid phase of distilled water and solid phase of encapsulated powder) to show that before
and after centrifuging the encapsulated powder does not mix with distilled water. This shows that cinnamaldehyde
is still encapsulated in chitosan nanoparticles.

3.2.2. Colour, shape and odor tests
Color, shape and odor tests were carried out to determine the characteristics of encapsulated powder
preparations and as a simple initial introduction by using five human senses. The test results show that all formulas
have similarities in terms of shape and smell. After 4 weeks the formulations remain in powder form and the
smell is still typical of cinnamaldehyde. Encapsulated powder preparations have different colors at each tested
temperature, but no changes occur every week. The formulations at the temperature of 4°, 30 and 60°C show
yellow, orange and solid orange colour, respectively.

3.2.3. In vitro test of cinnamaldehyde release
The release of cinnamaldehyde in chitosan nanoparticles was carried out on an acid medium with pH
1.2 to simulate the pH of gastric while medium alkaline fluids with pH 7.4 to simulate the pH of intestinal fluid.
The release test was carried out using an orbital shaker at 37°C with a stirring speed of 100 rpm. 37°C temperature
was used to resemble human body temperature and stirring aimed to describe bowel movements. The time
used in the release test was adjusted to the digestion time in the human body, which was about 1-3 hours in acidic
medium and 4±1.5 hours in alkaline medium [16]. Measurement of percentage release using standard
cinnamaldehyde graphs on acid and base medium.

Cinnamaldehyde nanoencapsulation aims to hold the rate of drug release in the stomach. The profile of drug or
active substance release is determined by the cross-link density of the microspheres, the size, and the initial
content of the drug [18]. Increasing cross-link inhibits swelling of beads in the medium and diffusion of the drug
which results in a lower release rate. Smaller beads have a wider contact area with media so that they support faster
drug release compared to larger beads [18]. The mechanism of drug or active substance release begins
with the swelling process when the beads come into contact with the dissolution medium followed by liquid
penetration into the matrix [19] resulting in a tenuous polymer structure [20].
Granule formulation (F) consists of F1 (chitosan), F2 (encapsulated powder) and F3 (cinnamaldehyde). The mucoadhesive test was carried out by spreading the granule formulation on the mucosa of the rat and left it in contact between the granule and the mucosa for 5 minutes. It was then eluted with acidic medium of pH 1.2 and alkaline medium of pH 7.4, for 10 minutes. The results of mucoadhesive tests on rat stomach and intestine are shown in Figure 5.

![Figure 2. Cinnamaldehyde release in acidic medium at pH 1.2](image)

The release of cinnamaldehyde on acidic medium at pH 1.2 within 5 minutes was 53.5% (Fig 2). It shows that quite large number of cinnamaldehyde has been released in the media which means that the encapsulation has begun to break down. The presence of cinnamaldehyde in the media is caused by protonation of \(\sim\text{NH}_2\) group of chitosan which is not crosslinked with TPP [21]. Swelling then occurs in which the liquid enter the polymer matrix causing cinnamaldehyde to diffuse into the external environment.

![Figure 3. Cinnamaldehyde release in alkaline medium at pH 7.4](image)

Figure 3 shows the release of cinnamaldehyde after 5 minutes was 51%. This result is greater than the release in acidic media in the same minute, which is caused by deprotonation in alkaline media. Lin et al. [22] stated that chitosan-TPP particles become unstable and begin to break at pH>7.2 due to deprotonation of the amino group of chitosan.

Figure 3 shows that with the increasing incubation time the release of cinnamaldehyde is increase, which is 61% in the 360th minute. This shows that the crosslink between chitosan and tripolyphosphate is broken resulted in the releasing of cinnamaldehyde [6].

3.3. Mucoadhesive test

This mucoadhesive test aims to look at the adhesion strength of granule formulas in the rat stomach and intestinal mucosa. The mucoadhesive system can be used to target drugs to certain parts of the body for long periods of time to improve the bioavailability of the drug [23]. Bioadhesive is the attachment of either synthesis or non-synthesis material in biological tissue for a long period of time. The term mucoadhesion refers to the case of bioadhesion where the mucosa is the biological tissue as the site attachment [24].

![Figure 4. Mucoadhesive test on stomach and intestine of white rats](image)

Figure 4 shows that all formulas have high mucoadhesive strength. This is due to the adhesion process that occurs in each formula with mucin in the rat stomach and intestinal mucous membranes.

Figure 6 shows that the mucoadhesive strength of all formulas in the gastric mucosa are higher than in the intestinal mucosa. This is because protonation occurs in the stomach so that many positive charges are formed. The more positive charges, the more ionic bonds are formed by the negative charge of mucin [25, 26]. F3 data showed that without using chitosan, granules attached to the stomach or intestine were less compared to F1 and F2 using chitosan polymer. In F3, it does not form electrostatic interactions with mucin. Cinnamaldehyde is possible to perform hydrogen binding with gastric or intestinal mucin, whereas in F1 and F2 it can interact electrostatically between chitosan and mucin. Figure 5 shows the approach to hydrogen bonding that might occur between cinnamaldehyde and gastric or intestinal mucin.
Figure 5. Hydrogen bonding between cinnamaldehyde with glutamic acid and galactose

In F1 which is a chitosan polymer, the percentage of granules attached to the stomach is 98.02% and in the intestine is 89.23%, while F2 which is chitosan–cinnamaldehyde nanoparticles has a smaller percentage in stomach of 91.5% and in the intestine of 84.61%. The both formulas contain chitosan polymers, but F2 contains chitosan in nanoparticle form and is crosslinked with triplyphosphate so that the amines are relatively few to interact with mucin. In addition, a tight matrix cause steric resistance to interact with mucin. As a result, the tendency of chitosan nanoparticles to mucoadhesive is reduced [6].

4. Conclusion

It can be concluded that the cinnamaldehyde content is quite stable and its specific gravity, pH, centrifugation and organoleptic of cinnamaldehyde powder do not experience significant changes. The chitosan–cinnamaldehyde nanoparticles encapsulated powder has mucoadhesive capacity of 91.5% in the gastric mucosa and 84.61% in the intestinal mucosa. The release of cinnamaldehyde in acidic media pH 1.2 for 180 minutes was 83.4%, whereas in alkaline media pH 7.4 for 360 minutes was 61%. The encapsulated powders show better mucoadhesive properties than cinnamaldehyde and the presence of chitosan nanoparticles can improve the bioavailability of cinnamaldehyde.

5. References


